STW

Programme

At the ILCA STW24, participants can anticipate discussions on:

Novel immunotherapy combinations and molecularly targeted agents.
Systemic therapies for patients with HCC, CCA and BTC, form the early to the advanced setting
The role of a multidisciplinary team in the management of liver cancer.

Day 1 – 26th April 2024

TIME	TOPIC	SPEAKER
9.00-9.05	Welcome and Introductions	Lorenza Rimassa, Italy Tim Meyer, UK
	Session 1: Systemic Therapy Introduction by session chairs: Lorenza Rimassa & Ghassan Abou-Alfa
09.05-09.20	A Patient’s Perspective	Helen Morement, UK
09.20-09.40	Selection of first-line therapy for HCC	Lorenza Rimassa, Italy
09.40-10.00	Selection of second-line therapy HCC	Massimo Iavarone, Italy
10.00-10.20	Selection of first-line therapy for BTC	Mairead McNamara, UK
10.20-10.40	Selection of second-line therapy BTC	Chiara Braconi, UK
10.40-11.00	Discussion
11.00-11.20	Coffee Break
	Session 2: Systemic therapy for early disease Introduction by session chairs: Chiara Braconi & Tim Meyer
11.20-11.40	Adjuvant and neoadjuvant systemic therapy for resectable HCC	Gonzalo Sapisochin, Canada
11.40-12.00	Adjuvant and neoadjuvant systemic therapy for resectable BTC	John Primrose, UK
12.00-12.20	Systemic therapy in the setting of transplantation	Parissa Tabrizian, USA
12.20-12.40	Discussion
12.40-13.30	Lunch
13.30-14.30	MDT discussion 4 cases	Panel 1. Chair, Oncology, Hepatology, Surgery and Radiology from present faculty
	Session 3: Molecular stratification and trial endpoints for systemic therapy Introduction by session chairs: Lorenza Rimassa & Josep Llovet
14.30-14.50	Stratification factors and predictive biomarkers in HCC	Josep Llovet, Spain
14.50-15.10	Molecular stratification for BTC	John Bridgewater, UK
15.10-15.30	Endpoints for phase III trials in liver cancer	Maria Reig, Spain
15.30-15.50	Patient reported outcomes in clinical trials for HCC and BTC	Peter Galle, Germany
15.50-16.10	Discussion
16.10-16.30	Coffee Break
	Session 4: Additional applications for systemic therapy Introduction by session chairs: Maria Reig & Tim Meyer
16.30-16.50	Systemic therapy for patients with Child Pugh B liver disease	Tim Meyer, UK
16.50-17.10	Systemic therapy for mixed HCC:CC
17.10-17.30	Rare subtypes – Fibrolamellar and sarcomatoid tumours	Ghassan Abou-Alfa, USA
17.30-17.50	Management of HCC in patients with HIV	David J. Pinato, UK

Day 2 – 27th April 2024

TIME	TOPIC	SPEAKER
09.00-09.05	Welcome and Introductions	Lorenza Rimassa, Italy Tim Meyer, UK
	Session 5: Emerging therapies Introduction by session chairs: Lorenza Rimassa & Juliene Edeline
09.05-09.20	Combination of systemic therapy with TACE in HCC	Maxime Ronot, France
09.20-09.40	Combining systemic therapy with radiotherapy in HCC	Laura Dawson, Canada
09.40-10.00	Combining systemic therapy with locoregional therapy in BTC	Julien Edeline, France
10.00-11.00	MDT discussion 4 cases	Panel 2. Chair, Oncology, Hepatology, Surgery and Radiology from present faculty
11.00-11.20	Coffee Break
	Session 6 Introduction by session chairs: Maria Hawkins & Tim Meyer
11.40-12.00	Mangement of oligometastatic disease	Maria Hawkins, UK
12.00-12.20	Role of intra-arterial chemotherapy	Stephen L. Chan, Hong Kong
12.20-12.40	Cellular therapy for liver cancer	Claire Roddie, UK
12.40-13.00	Novel and emerging systemic therapies for HCC	Bruno Sangro, Spain
13.00-13.20	Novel and emerging therapies for BTC	Maeve Lowery, Ireland
13.20-13.40	Discussion
13.40-13.50	Close	Lorenza Rimassa, Italy Tim Meyer, UK